HUBEI JUMPCAN PHARMACEUTICAL CO., LTD Class A

HUBEI JUMPCAN PHARMACEUTICAL CO., LTD Class A

SSSE:600566
31.18
CNY
+0.30
(+0.97%)
1.97EPS
12.91P/E
23.62BMarket Cap
Apr 12Next Earn
HUBEI JUMPCAN PHARMACEUTICAL CO., LTD Class A
SSE:600566
(Shanghai Stock Exchange)

Recent

price

31.18

P/E

ratio

12.91

div

yld

5.70%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
1.71
1.74
3.15
4.01
3.85
4.83
5.86
6.96
8.88
8.51
7.39
8.61
10.11
10.53
8.74
6.75
6.47
Revenue per Share
0.06
0.06
0.39
0.66
0.67
0.88
1.17
1.51
2.08
1.99
1.53
1.94
2.44
3.08
2.76
1.93
1.99
Basic EPS, GAAP
-0.18
-0.44
-0.01
0.03
0.41
0.32
0.74
0.55
1.28
1.96
1.62
1.86
2.67
3.45
2.18
1.2
- -
Free Cash Flow per Basic Share
0.09
0.09
0.54
0.03
0.05
0.4
0.69
0.73
1
1.23
1.21
0.46
0.68
0.9
1.33
2.09
1.78
Dividend per Share
3.76
3.8
5.42
1.54
2.94
3.41
4.52
5.44
6.73
7.49
8.74
10.26
12.3
14.48
15.95
15.85
15.29
Book Value per Share
3.56
3.62
5.18
1.36
2.75
2.93
4.03
4.96
6.13
6.87
8.23
9.76
11.77
13.96
15.43
15.3
14.64
Tangible Book Value per Share
138
138
609
610
775
780
798
810
811
816
835
886
890
916
917
921
915
Basic Weighted Avg Shares
237
240
1,920
2,448
2,986
3,768
4,678
5,642
7,208
6,940
6,165
7,631
8,996
9,655
8,017
6,219
5,924
Sales/Revenue/Turnover
9.19
7.91
13.05
17.73
18.74
19.93
22.48
24.28
26.23
26.13
22.73
22.15
25.68
30.05
30.18
30.19
31.99
Operating Margin (%)
21
23
47
61
81
109
117
152
176
232
281
294
309
303
308
311
- -
Depreciation Expense
8
8
238
403
519
687
934
1,223
1,688
1,623
1,277
1,719
2,171
2,823
2,532
1,778
1,816
Net Income, GAAP
2.85
4.15
17.2
13.37
14.1
14.56
14.12
14.74
14.62
14.27
13.91
11.96
13.41
14.26
14.83
17.76
15.93
Effective Tax Rate (%)
3.57
3.29
12.38
16.45
17.39
18.22
19.97
21.68
23.42
23.39
20.72
22.53
24.13
29.24
31.58
28.59
30.66
Profit Margin (%)
15
89
-95
115
943
878
1,527
2,222
2,691
3,072
4,607
5,322
7,749
9,644
11,164
11,304
10,803
Working Capital
- -
95
110
- -
- -
- -
- -
698
553
576
605
1
- -
1
1
1
19
LT Debt
520
527
750
1,152
2,294
2,713
3,688
4,402
5,480
6,104
7,763
9,131
11,352
13,369
14,726
14,633
14,108
Total Equity
0.98
0.59
22.21
28.27
24.29
24.38
28.25
26.42
29.1
25.03
16.75
18.73
19.38
21.14
16.19
11.4
12.1
Return on Invested Capital (%)
2.75
2.37
26.09
33.1
26.24
26.18
29.19
27.94
30.85
25.94
17.35
19.32
20.42
21.66
17.04
11.56
12.56
Return on Capital (%)
1.64
1.52
37.3
42.37
30.14
27.67
29.54
30.36
34.16
28.02
18.42
20.37
21.23
22.87
18.05
12.13
13.16
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
817
1,418
1,246
LT Borrowings
21
- -
- -
LT Finance Leases
1
17
19
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
922
922
922
Market Capitalization
24,258
20,453
23,625

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
14,217
13,438
13,589
Cash, Cash Equivalents & STI
12,576
11,770
11,760
Accounts Receivable, Net
1,109
1,143
1,246
Inventories
370
400
411
Total Current Liabilities
2,605
2,976
2,786
Payables & Accruals
- -
- -
- -
ST Debt
817
1,418
1,246
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
18.76%
13.84%
-0.64%
Free Cash Flow
30.24%
3.51%
-44.94%
Net Income, GAAP
13.07%
10.16%
-29.77%
Sales/Revenue/Turnover
6.72%
1.92%
-22.43%
Total Cash Common Dividend
27.4%
26.15%
58.38%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2,403
1,632
1,771
2,212
8,017
2025
1,525
1,223
- -
2,287
6,219
2026
1,207
1,121
1,309
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.92
1.1
0.62
0.69
2.76
2025
0.48
0.31
- -
0.82
1.93
2026
0.44
0.42
0.3
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
2.66
0.01
0.01
1.33
2025
- -
2.09
- -
0.01
2.09
2026
0.01
1.74
0.01
- -
- -
Business
Hubei Jumpcan Pharmaceutical Co., Ltd. (600566.SS) is a China-based pharmaceutical company engaged in the research, development, production, and sale of pharmaceutical products, including chemical drugs, biological preparations, and traditional Chinese medicines. The company offers a range of core products such as cardiovascular medications, anti-infective drugs, nervous system therapeutics, and digestive system treatments; its key brands include proprietary formulations like Jumpcan-branded tablets and injectables targeted at hospitals, clinics, and retail pharmacies across China. Founded in 1993 and headquartered in Shiyan, Hubei Province, Jumpcan operates primarily in the domestic market with manufacturing facilities concentrated in central China, serving major customer segments in the healthcare sector including public hospitals and pharmaceutical wholesalers. In recent developments, the company has focused on expanding its production capacity through strategic investments in new facilities and technology upgrades, with no major acquisitions, partnerships, or name changes reported in the last 1-2 years as of late 2025. Jumpcan continues to emphasize R&D in innovative generics and biosimilars to align with China's national healthcare reforms, including participation in volume-based procurement programs that have shaped its competitive positioning. The firm maintains a straightforward corporate structure without notable subsidiaries or parent affiliations, concentrating operations within the mainland Chinese pharmaceutical industry.